A prospective study on the treatment of retinoblastoma in 72 patients

Abstract

Seventy‐two patients with retinoblastoma (RTB) (unilateral [47 patients] and bilateral [25 patients]) were studied for a period of 6 years. Treatment consisted of enucleation of those eyes that had severe involvement and was followed by radiation therapy and/or chemotherapy (systemic or intrathecal) according to clinical pathologic staging. All patients who underwent nonsurgical treatment received systemic chemotherapy. Intrathecal chemotherapy was administered when there was involvement of the central nervous system. Nonsurgical treatment consisted of radiation therapy and/or light coagulation, followed by enucleation if there was no response. The overall survival rates were 79% for unilateral disease (median follow‐up time, 63 months) and 72% for bilateral disease (median follow‐up time, 81 months). Vision was regained in 14 of 21 conserved eyes.

Successful treatment of metastatic retinoblastoma

“…Despite some reports of long term event free survival, 7-9 the bulk of the evidence suggests that the prognosis remains grim with such an approach. [10][11][12] Many centers have intensified chemotherapy with ASCR for malignancies, and two case reports have suggested that such an approach might be beneficial for patients with metastatic retinoblastoma. 13,14 Subsequently, Institut Curie investigators treated 25 patients with high risk retinoblastoma with high dose carboplatin, etoposide, and cyclophosphamide followed by ASCR.…”

Postenucleation Adjuvant Chemotherapy With Vincristine, Etoposide, and Carboplatin for the Treatment of High-Risk Retinoblastoma

“…The metastatic rate has ranged from 4% in a study of 26 cases in which vincristine sulfate and cyclophosphamide was used to 33% in a study of 24 cases in which vincristine sulfate, cyclophosphamide, and doxorubicin was used. 26,27 Mustafa and associates 30 studied the effect of vincristine sulfate, doxorubicin, and cyclophosphamide in high-risk RB and found distant metastasis and subsequent death in 19% cases. They concluded that alternative chemotherapeutic agents should be considered for patients with such high-risk features.…”

Lack of Tir Ubiquitylation Contributes to Enteropathogenic E. coli Remaining Extracellular During Nonphagocytic Cell Infections

“…Adjuvant chemotherapy is not under discussion in these cases, as well as those with trans‐scleral invasion because a microscopic tumor residue is present. The traditional approach for the postenucleation treatment of these patients include adjuvant systemic and intrathecal chemotherapy along with radiotherapy 6, 9, 14, 38, 39. The survival rate for these patients ranged from 40% to 70% in such studies.…”